EPITHELIAL OVARIAN CANCER

This study tests a new drug called BL-B01D1 against standard chemotherapy in 384 adults with ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based treatment. The goal is to see if BL-B01D1 can slow cancer growth and improve survival. Pa…

This study tests a new treatment using specially engineered natural killer (NK) cells to attack cancer cells in people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalized based on the specific …

This study tests a new treatment called EB-DUALNK for adults with ovarian cancer that has come back or not responded to standard therapies. The treatment uses specially engineered natural killer (NK) cells designed to target two cancer-related markers at once. Participants first …

This study tests whether adding daphnetin capsules to standard chemotherapy and targeted therapy can help control advanced ovarian cancer (stage III-IV) after initial surgery. About 98 participants will receive the treatment and be monitored for side effects and cancer progressio…

This study tests a personalized vaccine made from a patient's own tumor cells and immune cells. The goal is to see if the vaccine can train the immune system to fight ovarian cancer more effectively. Ten women with advanced ovarian cancer will receive the vaccine alongside standa…

This early-phase study tests whether a new treatment using a patient's own modified immune cells (called CAR T cells) is safe for women with ovarian cancer that came back after standard platinum-based chemotherapy. The cells are designed to target a protein called B7-H3 found on …

This study tests a drug called TORL-1-23 in 230 women with advanced ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy and has a specific marker (claudin 6). The goal is to see if the drug can shrink tumors and how safe it is. Participa…

This study tests if removing lymph nodes near the liver (hepato-celiac lymphadenectomy) can help control advanced or recurrent ovarian cancer. About 94 women with stage III/IV or platinum-sensitive recurrent ovarian cancer will receive this surgery. Researchers will track how man…

This early-stage study tests an experimental treatment called 27T51, a type of immune cell therapy (CAR T) designed to target a protein called MUC16 found on certain cancer cells. The study involves about 90 women with ovarian, peritoneal, or fallopian tube cancer that has come b…

This study tests whether a natural compound called isoquercetin can reduce blood markers linked to dangerous clots in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal is to see if the s…

This early-stage study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The goal is to find safe doses and see if th…

This study tests whether adding a blood thinner called tinzaparin to standard chemotherapy can help fight advanced ovarian cancer. Researchers will measure changes in a tumor marker (CA-125) and other health indicators in 40 women with stage III-IV disease. The goal is to see if …

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer. About 500 newly diagnosed adults will receive either the drug combination or chemotherapy …

This study tests whether a new drug called AZD5335 works better than current treatments for women with a hard-to-treat type of ovarian cancer. About 1,100 women whose cancer has stopped responding to platinum chemotherapy will be randomly assigned to get AZD5335 or standard thera…

This study is testing an experimental drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their…

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study is for people with advanced ovarian cancer who are scheduled for surgery. It tests whether taking a drug called olaparib alone or with another drug called durvalumab for a short time before surgery is safe and practical. The goal is to see if this approach can be done …

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This study tests a new imaging agent called [18F]FPyQCP for PET scans to better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the agent and undergo PET/CT imaging. The goal is to see if it i…

This study looks at whether timed fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for women with advanced ovarian cancer receiving chemotherapy before surgery. About 20 participants will either follow a fasting schedule or standard diet for 6-9 weeks. Re…

This study tests whether a combination of two drugs (propranolol and etodolac) plus mind-body training and music therapy can reduce stress in women with advanced ovarian cancer undergoing surgery. About 35 participants will be randomly assigned to receive this bundle or standard …

This study looks at whether a program of exercise and nutrition (called prehabilitation) can help people aged 65 and older with advanced ovarian or pancreatic cancer get ready for surgery while they receive chemotherapy. The main goal is to see if participants can stick with the …

This study looks at how the immune system behaves in people with newly diagnosed ovarian cancer. Researchers will collect blood, tumor tissue, and other samples from about 74 participants to see which immune cells are present and how they relate to how long the cancer stays under…

This study is looking for immune markers in the blood of 300 people with ovarian cancer to see if they can predict how the disease will progress. Participants give blood samples before starting standard treatment. The goal is to better understand the immune system's role in ovari…

This study aims to understand why some ovarian cancers become resistant to platinum-based chemotherapy. Researchers will follow 600 patients for 5 years, collecting medical data and biological samples (blood, tumor, and fluid samples) during standard care. No extra procedures are…